Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus

Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

Techniques: Control

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Characteristics of Patients in the Studies Evaluated for, but Excluded from, This Meta-Analysis

Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

Techniques: Control, Modification, Transplantation Assay

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Summary of Findings: Gemigliptin Compared to Control in the Management of Type 2 Diabetes Mellitus

Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

Techniques: Control

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Forest plot highlighting the impact of gemigliptin as compared to the active control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

Techniques: Control, Standard Deviation

Journal: Endocrinology and Metabolism

Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

doi: 10.3803/EnM.2020.818

Figure Lengend Snippet: Forest plot highlighting the impact of gemigliptin as compared to the passive control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

Techniques: Control, Standard Deviation

Journal: Journal of Diabetes Science and Technology

Article Title: Computerized Prompting and Feedback of Diabetes Care: A Review of the Literature

doi:

Figure Lengend Snippet: Reminders and Process / Outcome Measures a

Article Snippet: Outcome : HbA1c < 7.0% (NS); mean HbA1c (NS); mean reduction HbA1c (NS); LDL < 100 mg/dl (NS); mean LDL cholesterol (NS); mean reduction LDL cholesterol (NS); blood pressure < 130/85 mmHg (NS); mean systolic blood pressure (NS); mean diastolic blood pressure (NS) Ziemer et al . (2006) 26 glucose levels, HbA1c, weight, blood pressure, use of medications Process : therapy intensification in response to glucose level (NS) Open in a separate window a LDL, low-density lipoprotein; NCQA, National Committee for Quality Assurance; NS, not significant Reminders and Process / Outcome Measures a Process and Outcome Measures Fifty processes and 57 outcomes were measured in the 15 studies ( ).

Techniques: Control, Medications